Drug Profile


Alternative Names: BMS 18029; BMS 180291; BMS 180291A; Boxaban; CPI 211; Hepatoren; Portaban; VasculanTM

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals
  • Class Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Hepatorenal syndrome; Portal hypertension; Systemic scleroderma
  • Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 10 Nov 2017 Cumberland Pharmaceuticals plans a phase I trial for Duchenne Muscular Dystrophy in USA (NCT03340675)
  • 17 Jul 2017 Cumberland Pharmaceuticals initiates enrolment in a phase II trial for Asthma (aspirin exacerbated respiratory disease) in USA (PO) (NCT03028350)
  • 14 Sep 2016 Phase-II clinical trials in Portal hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top